304 related articles for article (PubMed ID: 21835933)
1. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
Safra T; Borgato L; Nicoletto MO; Rolnitzky L; Pelles-Avraham S; Geva R; Donach ME; Curtin J; Novetsky A; Grenader T; Lai WC; Gabizon A; Boyd L; Muggia F
Mol Cancer Ther; 2011 Oct; 10(10):2000-7. PubMed ID: 21835933
[TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Lawrie TA; Bryant A; Cameron A; Gray E; Morrison J
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006910. PubMed ID: 23835762
[TBL] [Abstract][Full Text] [Related]
3. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
[TBL] [Abstract][Full Text] [Related]
4. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Park YC; Parekh TV; Poveda AM
Eur J Cancer; 2012 Oct; 48(15):2361-8. PubMed ID: 22541893
[TBL] [Abstract][Full Text] [Related]
5. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer.
Safra T; Rogowski O; Muggia FM
Int J Gynecol Cancer; 2014 Mar; 24(3):488-95. PubMed ID: 24457564
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
Lawrie TA; Rabbie R; Thoma C; Morrison J
Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010482. PubMed ID: 24142521
[TBL] [Abstract][Full Text] [Related]
7. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW
Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659
[TBL] [Abstract][Full Text] [Related]
8. Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer.
Nicoletto MO; Bertorelle R; Borgato L; De Salvo GL; Artioli G; Lombardi G; Zustovich F; Marcato R; Parenti A; Montagna M; Donach ME
Int J Gynecol Cancer; 2009 Aug; 19(6):1022-8. PubMed ID: 19820363
[TBL] [Abstract][Full Text] [Related]
9. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer.
Adams SF; Marsh EB; Elmasri W; Halberstadt S; Vandecker S; Sammel MD; Bradbury AR; Daly M; Karlan B; Rubin SC
Gynecol Oncol; 2011 Dec; 123(3):486-91. PubMed ID: 21945552
[TBL] [Abstract][Full Text] [Related]
10. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
[TBL] [Abstract][Full Text] [Related]
11. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
13. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
14. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
Monk BJ; Brady MF; Aghajanian C; Lankes HA; Rizack T; Leach J; Fowler JM; Higgins R; Hanjani P; Morgan M; Edwards R; Bradley W; Kolevska T; Foukas P; Swisher EM; Anderson KS; Gottardo R; Bryan JK; Newkirk M; Manjarrez KL; Mannel RS; Hershberg RM; Coukos G
Ann Oncol; 2017 May; 28(5):996-1004. PubMed ID: 28453702
[TBL] [Abstract][Full Text] [Related]
15. Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer.
Nomura H; Tsuda H; Kataoka F; Chiyoda T; Yamagami W; Tominaga E; Susumu N; Aoki D
Eur J Gynaecol Oncol; 2012; 33(1):86-9. PubMed ID: 22439412
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer.
Mayer C; Brucker J; Schuetz F; Domschke C; Bechstein S; Heil J; Golatta M; Wallwiener M; Sohn C; Schneeweiss A; Rom J
Arch Gynecol Obstet; 2016 Jul; 294(1):123-9. PubMed ID: 26498757
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN).
Lee YJ; Seol A; Lee M; Kim JW; Kim HS; Kim K; Suh DH; Kim S; Kim SW; Lee JY
In Vivo; 2022; 36(4):1949-1958. PubMed ID: 35738633
[TBL] [Abstract][Full Text] [Related]
18. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer.
Chambers LM; Pendlebury A; Rose PG; Yao M; DeBernardo R
Gynecol Oncol; 2020 Aug; 158(2):309-315. PubMed ID: 32499072
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer treatment in mutation carriers/BRCAness.
Lorusso D; Perotto S
Minerva Ginecol; 2016 Oct; 68(5):566-78. PubMed ID: 26785283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]